On October 28, 2016 The board (the " Board ") of directors (the "Directors ) of the Company reported that Nanjing Legend Biotech Co., Ltd.* 南京傳奇生物科技有限公 司 (" Nanjing Legend "), a wholly-owned subsidiary of the Company, has achieved promising results in its research and development in immunotherapy technology for cancer cure (Press release, GenScript, OCT 28, 2016, View Source [SID1234519380]). Schedule your 30 min Free 1stOncology Demo! Nanjing Legend has been focusing on the research and development of chimeric antigen receptor T ("CAR-T"/LCAR-B38M CAR-T Cells) cell technology in immunotherapy. Nanjing Legend has collaborated with a 3A hospital in China and provided proprietary CAR-T cell technology to treat Multiple Myeloma for clinical research. The Board is pleased to announce that the clinical research yields promising results.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Multiple Myeloma is a fatal plasma cell neoplasm affecting one to five per 100,000 individuals. As CAR-T cell therapy is demonstrating clinical efficacy in treating certain kinds of leukemia and lymphoma, increasing attempts in developing CAR-T cell therapy to treat Multiple Myeloma have been made worldwide. The Group believes that CAR-T cell technology has significant potential in clinical cancer therapeutics, the promising clinical research results further boost the Group’s plan to capture the growth opportunities in the clinical research services market by continuing its research and development in cancer immunotherapy and expanding into the development and application of CAR-T cell therapy in the future.
Author: [email protected]
AASLD : Preclinical characterization of GNS561 a novel first in class autophagy inhibitor able to kill hepatocellular carcinoma cancer stem cell
On October 31, 2016 GenoScience reported preclinical characterization of GNS561 a novel first in class autophagy inhibitor able to kill hepatocellular carcinoma cancer stem cell (Press release, GenoScience, OCT 31, 2016, View Source [SID1234516098]). Schedule your 30 min Free 1stOncology Demo! In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. In recent years, highly tumorigenic subpopulations of cancer cells named Cancer Stem Cells (CSCs) have been implicated in post-treatment tumor recurrence. Indeed, CSCs are resistant to chemotherapy, and they have the ability to regenerate all the cell types within the tumor.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For this reason, innovative drugs with original mechanism of action which tackle CSCs would likely improve cancer treatment of patients.
Antitumor activity of GNS561 was tested on a panel of cancer cell lines. Its effect on HCC CSCs subpopulation was assessed by flow cytometry (ALDH activity, CD133 expression) and by sphere formation assay. Tolerance and plasma and liver pharmacokinetic were evaluated after single and repeated dosing in mice and rats. In vivo GNS561 activity was tested in orthotopic mouse models.
Results: GNS561 demonstrated autophagy inhibition and apoptosis induction activities related to lysosome disruption.
It showed potent antitumor activity against a panel of human cancer cell lines. In HCC cell lines, GNS 561 was active on both whole populations (mean EC50 2μM) and subpopulations displaying CSC features (high ALDH and CD133 positivity). Further, GNS561 was effective against a panel of HCC tumors even from patients harboring sorafenib resistance. In mouse, GNS561 was found well tolerated and highly selectively trapped in the liver (exposure ratio liver/plasma about 170 animals), and showed a significant tumor growth inhibition in orthotopic HCC mouse models.
Conclusions: Our results provide a rationale for testing autophagy flux disruption as a novel therapeutic strategy for HCC. GNS561 is a liver selective drug active against both the whole tumor bulk and CSCs, which offers great promise for HCC treatment.
AbbVie Reports Third-Quarter 2016 Financial Results
On October 28, 2016 AbbVie (NYSE:ABBV) reported financial results for the third quarter ended September 30, 2016 (Press release, AbbVie, OCT 28, 2016, View Source [SID1234516062]). Schedule your 30 min Free 1stOncology Demo! "We delivered another strong quarter, with EPS growth ahead of our expectations. Year-to-date, we’ve driven strong commercial, operational and R&D execution, and we have advanced our pipeline and other strategic priorities," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "AbbVie represents a unique investment opportunity, offering both compelling growth, along with a strong return of capital to investors, including a rapidly growing dividend, which has grown 60 percent since we became an independent company nearly four years ago."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Third-Quarter Results
Worldwide reported net revenues were $6.43 billion in the third quarter, up 8.2 percent. Worldwide adjusted net revenues increased 8.0 percent, excluding a 0.6 percent unfavorable impact from foreign exchange rate fluctuations.
Global HUMIRA sales increased 11.3 percent on a reported basis. Operational HUMIRA sales increased 12.1 percent, excluding a 0.8 percent impact from foreign exchange. Strong global growth was driven by continued momentum across all three major market categories – rheumatology, dermatology and gastroenterology.
Third-quarter global IMBRUVICA net revenue was $501 million, with U.S. sales of $437 million and international profit sharing of $64 million for the quarter. Total company sales growth was also driven by strong operational growth from Creon and Duodopa.
On a GAAP basis, the gross margin ratio in the third quarter was 76.6 percent. The adjusted gross margin ratio was 80.7 percent.
On a GAAP basis, selling, general and administrative expense was 21.5 percent of net revenues. The adjusted SG&A expense was 21.4 percent of net revenues.
On a GAAP basis, research and development expense was 17.2 percent of net revenues. The adjusted R&D expense was 16.5 percent, reflecting funding actions supporting all stages of our pipeline.
On a GAAP basis, the operating margin in the third quarter was 36.7 percent. The adjusted operating margin was 42.8 percent.
Net interest expense was $250 million. On a GAAP basis, the tax rate in the quarter was 20.7 percent. The adjusted tax rate was 19.9 percent.
Diluted earnings per share in the third quarter was $0.97 on a GAAP basis. Adjusted diluted EPS, excluding intangible asset amortization expense and other specified items, was $1.21, up 7.1 percent.
Key Events from the Third Quarter
AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for VENCLYXTO (venetoclax) for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) with chromosome 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or in patients without the 17p deletion or TP53 mutations who have failed both chemotherapy and a B-cell pathway inhibitor. AbbVie also announced that it had received Canadian regulatory approval of Venclexta (venetoclax) for patients with R/R CLL with chromosome 17p deletion. Earlier this year, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Venclexta for the treatment of patients with CLL with 17p deletion who have received at least one prior therapy. Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group.
AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for IMBRUVICA to treat patients with marginal zone lymphoma (MZL). MZL is a slow-growing form of non-Hodgkin’s lymphoma. If approved, MZL will be the fifth unique type of blood cancer indication for IMBRUVICA.
AbbVie continued to advance studies of rovalpituzumab tesirine (Rova-T), a novel biomarker-specific therapy that targets cancer stem cells and combines a targeted antibody that delivers a cytotoxic agent directly to cancer cells expressing delta-like protein 3 (DLL3). The expression of DLL3 suggests Rova-T may be useful across a range of neuroendocrine tumors, including a subset of small cell lung cancer (SCLC), metastatic melanoma, glioblastoma multiforme, prostate, pancreatic and colorectal cancers. AbbVie recently began enrollment of a Phase 1 eight-arm "basket study" in neuroendocrine tumors and a Phase 1/2 regimen selection study as a first-line treatment for SCLC.
AbbVie, in partnership with Boehringer Ingelheim (BI), completed patient enrollment for the Phase 3 pivotal program evaluating risankizumab in patients with moderate-to-severe plaque psoriasis. Data from three of the registrational studies are expected by the end of 2017. AbbVie and BI are also evaluating the potential of risankizumab in Crohn’s disease, psoriatic arthritis and asthma, with the initiation of the Phase 3 program in Crohn’s disease expected in the first half of 2017.
AbbVie received U.S. FDA Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1, including therapy with an NS5A inhibitor and/or protease inhibitor. BTD is intended to expedite the development and review of therapies for serious or life threatening conditions.
AbbVie is nearing completion of the registrational program for its next-generation HCV combination regimen of ABT-493 and ABT-530. Results from several of the Phase 3 studies, including 8-week data in treatment-naive, non-cirrhotic patients, as well as in patients who failed previous therapy with DAAs, will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in November. The company anticipates commercialization of the next-generation combination in 2017.
AbbVie and Biogen announced the European Commission (EC) approval for ZINBRYTA (daclizumab), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS). Approval from the U.S. FDA was received in May. These approvals were based on results from the Phase 3 DECIDE and SELECT trials which demonstrated that treatment with ZINBRYTA 150 mg, administered subcutaneously every four weeks, reduced the annualized relapse rate, as well as the risk of 24-week confirmed disability progression. ZINBRYTA improved results on key measures of MS disease activity in patients with RMS compared to AVONEX 30 mcg intramuscular injection administered weekly and placebo. The companies launched ZINBRYTA in the U.S. in August.
AbbVie and Biogen presented data at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London. The new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTATM achieved no evidence of disease activity (NEDA) compared to those taking AVONEX (interferon beta-1a) intramuscular injection. Additional new interim data from the long-term extension study, EXTEND, further affirm ZINBRYTA’s efficacy on clinically meaningful measures of multiple sclerosis disease activity and provide additional information supporting ZINBRYTA’s safety profile.
AbbVie and Neurocrine Biosciences, Inc. presented data from two replicate pivotal Phase 3 studies evaluating the efficacy and safety of Elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, in premenopausal women with endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress (ASRM). The data demonstrated that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea) and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. Phase 3 trials of Elagolix for the management of uterine fibroids are ongoing.
AbbVie Raises Full-Year 2016 Outlook
AbbVie is raising GAAP diluted EPS guidance for the full-year 2016 to $3.74 to $3.76. AbbVie is raising its adjusted diluted EPS guidance for the full-year 2016 to $4.80 to $4.82. The company’s 2016 adjusted diluted EPS guidance excludes $1.06 per share of intangible asset amortization expense, acquisition related costs and accounting impacts, the impact of the Venezuelan currency devaluation, and other specified items.
Company Declares Dividend Increase of 12 Percent
AbbVie is also announcing today that its board of directors declared an increase in the company’s quarterly cash dividend from $0.57 per share to $0.64 per share beginning with the dividend payable on February 15, 2017 to shareholders of record as of January 13, 2017. This reflects an increase of approximately 12 percent, continuing AbbVie’s strong commitment to returning cash to shareholders through a growing dividend. Since the company’s inception in 2013, AbbVie has increased its dividend by 60 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
10-Q – Quarterly report [Sections 13 or 15(d)]
Alder Biopharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Alder Biopharmaceuticals, 2017, OCT 27, 2016, View Source [SID1234521702]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Adaptive Biotechnologies Announces the Inclusion of NGS-Based MRD Assessment in the NCCN Clinical Practice Guidelines for Multiple Myeloma
On October 27, 2016 Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, reported that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma (Press release, Adaptive Biotechnologies, OCT 27, 2016, View Source [SID1234516105]). Results from these new innovative clinical tools can help inform treatment decisions for active symptomatic patients as well as those undergoing maintenance treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These clinical practice guidelines recommend the use of highly sensitive diagnostic tools with the ability to detect at least 1 cell among 100,000 normal cells and advise that testing should occur after each treatment stage (induction, high-dose therapy/ACST, consolidation, and maintenance) at times of suspected complete response. This unanimous recommendation from 27 of the nation’s leading experts in the field of Multiple Myeloma treatment and research signals a shift in the management of patients and supports regular assessment of MRD by new validated clinical tools. For more information, go to: View Source
"Advanced diagnostic tools are transforming patient management in Multiple Myeloma and other lymphoid malignancies," said C. Ola Landgren, MD, PhD, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center. "Robust new diagnostic tools along with advanced new treatment options are enabling clinicians to respond with the optimal intervention at the right time, which is changing the natural course of this disease."
"The approval of incredible new treatments for blood cancers continues to elevate the need for robust diagnostic tools, and we are excited that the NCCN recognizes the importance of regular MRD assessment throughout the care and management of Multiple Myeloma patients," said Chad Robins, President, Chief Executive Officer and Co-Founder of Adaptive Biotechnologies. "Adaptive is highly committed to providing a robust validated assay with the ability to assess levels of residual disease down to 1 cell in 1,000,000 cells using our proprietary clonoSEQ Assay. Making this important clinical tool available to patients around the world is a priority for Adaptive and supports our mission to improve patient care."
About Minimal Residual Disease
Minimal/measurable residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as the next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.
About the clonoSEQ Assay
Adaptive’s clonoSEQ Assay enables physicians to utilize next-generation sequencing-based measurable residual disease (MRD) detection to inform clinical decision-making for patients with lymphoid malignancies (blood cancers). With its ability to detect and identify cancer cells at a level as low as one per one million cells, the clonoSEQ Assay is ten to one hundred times more sensitive than other methods of MRD detection, allowing physicians to address possible recurrence earlier. The clonoSEQ Assay provides consistent, accurate results which allow physicians to track specific cancer cell clones over time and optimize treatments for better patient management. Adaptive is currently seeking regulatory review and clearance of the clonoSEQ Assay.